Aeglea BioTherapeutics · deck
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides
50 pages · 3 arc beats · 1 loops
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides
Aeglea BioTherapeutics · 2023-06 arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
12468101214161820222426283032343638404244464850
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 12 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Situation & Context 4 slides 100% 4/4 slides 100% 4/4 slides · 17 hits — 0/4 slides
75% 3/4 slides · 4 hits — 0/4 slides
100% 4/4 slides — 0/4 slides
Problem & Complication 4 slides 100% 4/4 slides 100% 4/4 slides · 20 hits — 0/4 slides
25% 1/4 slides 75% 3/4 slides 100% 4/4 slides — 0/4 slides
Solution & Approach 4 slides 100% 4/4 slides 100% 4/4 slides · 20 hits — 0/4 slides
25% 1/4 slides 100% 4/4 slides 100% 4/4 slides 100% 4/4 slides Slide inventory
50 every slide · same image gating as the playbook
03
The slide details a corporate acquisition and concurrent private placement financing.summarize
Open slide detailBeat · Situation & Context
05
The slide uses a Gantt-style visualization to show the development status of various drug candidates.plan_implementation
Open slide detailBeat · Problem & Complication
07
The chart uses a conceptual scatter plot to contrast current SOC with a future target state, emphasizing the need for higher efficacy and better convenience.frame_problem
Open slide detailBeat · Problem & Complication
08
The slide uses a numbered list format to present the company's core strategic pillars.present_solution
Open slide detailBeat · Problem & Complication
09
The chart illustrates the correlation between Cyno and Human half-life, showing YTE mAbs (Spyre's approach) outperforming WT mAbs.present_solution
10
The slide uses a visual metaphor of two antibodies merging into a single complex to represent combination therapy.cite_precedent
11
The Venn diagram shows the intersection of genetic targets (TL1A, IL-23, a4b7). The bar chart compares 'All-comers' vs 'CDx+' (companion diagnostic positive) pacite_precedent
12
The slide uses a Gantt-style visualization to show the progression of various drug programs (SPY001-SPY230).plan_implementation
13
The slide uses a matrix-like layout to map strategy (mAbs vs combinations) to specific programs and their development status (Discovery, IND-Enabling, Clinical)plan_implementation
15
The chart uses a vertical axis to categorize drugs by mechanism of action (α4β7, IL-23s, TNFαs, S1P1s, JAKs) and a horizontal axis for efficacy (Pbo-adjusted clcompare_peers
16
The table uses checkmarks for positive attributes and arrows for 'potential upside' to differentiate SPY001's superior profile.compare_peers
17
The slide uses a Y-shaped antibody diagram to annotate specific functional improvements.present_solution
18
The slide uses a structural model of the protein complex and two dose-response curves to demonstrate efficacy and selectivity.present_solution
19
The chart shows dose-response curves for cell binding. The table summarizes EC50 values.analyze_data
20
The chart shows a biphasic exponential decay curve for three datasets.analyze_data
21
The chart uses a regression line to correlate human and NHP half-lives, highlighting the 3.1x multiplier for YTE-modified antibodies.analyze_data
22
The slide uses a visual timeline/comparison to contrast the high injection frequency of the competitor with the lower frequency of SPY001.compare_peers
23
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.frame_problem
26
The slide uses a dual-axis approach: a bar chart for valuation benchmarks and a timeline for clinical milestones.size_opportunity
27
The slide uses a visual pipeline format to track progress from Discovery to Clinical stages for specific drug candidates.plan_implementation
28
The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axicompare_peers
29
Uses a checkmark matrix to highlight competitive advantages of SPY002.compare_peers
30
The slide uses an antibody diagram to annotate specific technical advantages of the SPY002 molecule.present_solution
31
The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.compare_peers
32
Includes two charts: a dose-response curve and a scatter plot of potency vs. binding specificity.compare_peers
33
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently compare_peers
34
The slide uses a 2x2 grid to summarize program strengths and a timeline for catalysts.present_solution
35
The slide uses a mountain-climbing metaphor to represent indication expansion.present_solution
36
The slide uses a Gantt-style visualization to show the progress of various drug candidates (SPY001-SPY230).plan_implementation
37
The slide uses a biological process diagram to illustrate drug targets (a4b7, TL1A, IL-23) and their corresponding therapeutic antibodies.present_solution
38
The slide uses a bar chart to illustrate additive clinical remission rates, with a table below providing additional clinical metrics (N, maintenance remission, analyze_data
39
The slide uses donut charts to represent remission rates and highlights the safety advantages of Spyre's gut-selective approach.compare_peers
40
Includes a specific note that this is an 'Illustrative example' and 'Preliminary; pending regulatory feedback'.plan_implementation
41
The slide uses a bispecific antibody illustration to represent the combination therapy approach.present_solution
42
The slide uses a Venn diagram to illustrate target overlap and a hierarchical tree to show potential combination therapy paths.present_solution
43
The slide uses a comparative bar chart structure to show the delta in efficacy when using a companion diagnostic (CDx).illustrate_case
45
The slide displays headshots of leadership and board members, followed by a grid of company logos representing their backgrounds or affiliations.other
46
The slide uses a table-based timeline format to track R&D progress and external data readouts.plan_implementation
47
The table uses a custom visualization for market cap range (min, IPO, today, max) and clinical stage progression.compare_peers
48
The table maps historical industry M&A deals to Spyre's internal pipeline development milestones (2025-2027).compare_peers
50
The slide uses a list-based format to highlight key organizational milestones and metrics.establish_context